This article explores the transition to the EU Clinical Trials Regulation (EU CTR), focusing on the operational challenges sponsors and applicants faced. Key topics include harmonizing country-specific documents prior to transition submissions, operational and functionality issues within the Clinical Trials Information System (CTIS), transparency requirements, and the need for regular updates on guidance and Q&A documents during the transition period. The article highlights the need for ongoing communication between stakeholders to address these challenges.
